2018
DOI: 10.1021/acsami.8b04962
|View full text |Cite
|
Sign up to set email alerts
|

Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery

Abstract: More than 20 years after its approval by the Food and Drug Administration (FDA), liposomal doxorubicin (DOX) is still the drug of choice for the treatment of breast cancer and other conditions such as ovarian cancer and multiple myeloma. Yet, despite the efforts, liposomal DOX did not satisfy expectations at the clinical level. When liposomal drugs enter a physiological environment, their surface gets coated by a dynamic biomolecular corona (BC). The BC changes liposome's synthetic identity, providing it with … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
48
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 60 publications
(48 citation statements)
references
References 70 publications
0
48
0
Order By: Relevance
“…19,20 Understanding and controlling this process has become increasingly important. 21,22 In cell culture fetal bovine or human serum are commonly used for cell maintenance and in vitro experiments. 23 Mirshafiee et al 24 and Schöttler et al 25 have already reported that protein sources such as fetal calf serum, human serum, human heparin plasma or human citrate plasma can significantly influence cellular uptake of nanocarriers and their protein adsorption patterns.…”
Section: Introductionmentioning
confidence: 99%
“…19,20 Understanding and controlling this process has become increasingly important. 21,22 In cell culture fetal bovine or human serum are commonly used for cell maintenance and in vitro experiments. 23 Mirshafiee et al 24 and Schöttler et al 25 have already reported that protein sources such as fetal calf serum, human serum, human heparin plasma or human citrate plasma can significantly influence cellular uptake of nanocarriers and their protein adsorption patterns.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, the protein corona formed in a complete cell culture medium inhibits the release of camptothecin (CPT, a hydrophobic antitumoral drug) from the pores of mesoporous silica NPs (MSNs) . However, for another important lipid‐based nanodrug, Doxove, which is similar to the commercial product Doxil containing the same lipid composition for doxorubicin (Dox) delivery, exposure to human plasma and protein corona formation may interfere with its integrity, possibly leading to a fraction of DOX leakage . In addition to establishing the drug release profile, acquiring a detailed understanding of the effect of the protein corona on uptake by targeted cells is an indispensable task for desirable drug delivery ( Figure ).…”
Section: Effect Of the Protein Corona On Pharmacokinetics Of Nanomedimentioning
confidence: 99%
“…In addition to establishing the drug release profile, acquiring a detailed understanding of the effect of the protein corona on uptake by targeted cells is an indispensable task for desirable drug delivery ( Figure ). Human protein binding reduces internalization of Doxoves in MCF7 and MDA‐MB‐435S human breast carcinoma cells because the opsonins, such as complements and immunoglobulins, are poorly enriched, but the apolipoproteins are well‐enriched. That liposome‐based nanocarriers prefer apolipoproteins has been verified by Pozzi et al as well.…”
Section: Effect Of the Protein Corona On Pharmacokinetics Of Nanomedimentioning
confidence: 99%
“…95 It has become clear that once in contact with blood, a liposome is coated with a dynamic corona, which changes the "biological identity" of the liposome such as its size and aggregation state. 96 Additionally, the interaction between ions and headgroups can lead to significant physical changes on the liposomes, such as vesicle fusion. 97 Alternative, clever methods are being explored and are entering clinical trials, such as the use of red blood cells as drug delivery devices.…”
Section: ■ Mechanoresponsive Drug Deliverymentioning
confidence: 99%